{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:43:23Z","timestamp":1792194203585,"version":"4.4.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.2215\/cjn.17981120","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T12:35:30Z","timestamp":1609245330000},"page":"3-5","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Safety of Tolvaptan in ADPKD"],"prefix":"10.2215","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04152837","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Dipal M.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-9961","authenticated-orcid":false,"given":"Neera K.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,29]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: Analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/ndt\/gfx079","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: The TEMPO 4:4 trial","volume":"32","author":"Torres","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2215\/CJN.10250620","article-title":"Multicenter study of long-term safety of tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"16","author":"Torres","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2215\/CJN.08170719","article-title":"A post hoc analysis of statin use in tolvaptan autosomal dominant polycystic kidney disease pivotal trials","volume":"15","author":"Shoaf","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ekir.2019.09.002","article-title":"Role of liver transplantation in tolvaptan-associated acute liver failure","volume":"4","author":"Endo","year":"2019","journal-title":"Kidney Int Rep"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.xkme.2019.11.008","article-title":"Quality of life in autosomal dominant polycystic kidney disease patients treated with tolvaptan","volume":"2","author":"Anderegg","year":"2020","journal-title":"Kidney Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.17981120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:15Z","timestamp":1786369515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.17981120"}},"subtitle":["Where Do We Stand?"],"short-title":[],"issued":{"date-parts":[[2020,12,29]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.17981120","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,29]]}}}